Goodwin Procter advised Aura Biosciences on the deal. Aura Biosciences, Inc. (Nasdaq: AURA) announced its initial public offering of 5,400,000 shares of common stock at a public...
Aura Biosciences’ $75.6 Million IPO
EQRx’s Merger with CM Life Sciences III
Goodwin Procter advised EQRx on the deal while White & Case LLP advised CM Life Sciences III Inc. EQRx, Inc. announced its definitive merger agreement with CM...
Intellia Therapeutics’ $690 Million Underwritten Public Offering
Goodwin Procter advised Intellia Therapeutics on the deal. Intellia Therapeutics, Inc. (Nasdaq: NTLA) announced its $690 million underwritten public offering on the heels of releasing the first-ever...
Doximity’s $605.8 Million IPO
Goodwin Procter LLP advised Doximity on the deal. Doximity (NYSE: DOCS) announced its initial public offering of 23,300,000 shares of its Class A common stock at a...
Ambrx Biopharma’s $126 Million IPO
Goodwin Procter LLP and JunHe advised Goldman Sachs & Co. LLC and the other underwriters on the deal, while Wilson Sonsini Goodrich & Rosati and Maples...
Privia Health Group’s $607.8 IPO
Goodwin Procter LLP advised the underwriters on the deal. Privia Health Group, Inc. (“Privia Health”) (Nasdaq: PRVA), a technology-driven, national physician enablement company that collaborates with...
Better Therapeutics’ $187 Million Merger Agreement with Mountain Crest Acquisition Corp II
Goodwin Procter LLP advised Better Therapeutics, Inc. on the deal. Better Therapeutics, Inc. announced its definitive merger agreement with Mountain Crest Acquisition Corp II (Nasdaq: MCAD;), a...